Table 2.
Serum concentrations of sCAMs and other assessed parameters at baseline and after 2 months of follow-up.
| Baseline | After 2-Month Follow-Up |
Δ (%) | p | |
|---|---|---|---|---|
| sE-selectin, ng/mL | 21.0 (14.3–23.0) |
21.6 (16.4–25.9) |
6.3 ± 45.3 | 0.39 |
| sP-selectin, ng/mL | 38.1 (31.9–55.8) |
41.1 (39.4–48.2) |
11.0 ± 46.2 | 0.17 |
| sVCAM-1, ng/mL | 624.6 (460.3–923.9) |
814.2 (684.6–1072.0) |
32.6 ± 54.5 | <0.05 |
| sICAM-1, ng/mL | 388.5 (314.9–484.1) |
464.8 (379.0–534.6) |
23.4 ± 52.5 | <0.05 |
| EpCAM, ng/mL | 0.76 (0.57–1.37) |
0.57 (0.51–0.68) |
−13.3 ± 42.9 | <0.05 |
| sIL6Ra, ng/mL | 3.38 (2.33–6.67) |
3.11 (2.57–3.85) |
−1.7 ± 46.8 | 0.11 |
| sTNF-R1, ng/mL | 0.84 (0.61–1.11) |
0.93 (0.69–1.13) |
22.6 ± 87.6 | 0.54 |
| sTNF-R2, ng/mL | 1.95 (0.98–2.50) |
1.92 (1.40–2.12) |
27.7 ± 91.4 | 0.57 |
Data are shown as mean values ± SD or medians (Q1–Q3). Δ—relative percentage change of the initial value.